To evaluate the indirect effect of four lipid-lowering drug targets (ANGPTL3, APOC3, LPL, and LDLR) on IBD, CD, and UC through gut microbiota and inflammatory cytokines, we carried out a mediation analysis utilizing both the effect estimates from two-step MR and the total effect from primary MR analysis. This evidence concerns the gene LPL and inflammatory bowel disease.